我是 LongbridgeAI，我可以總結文章信息。ABL Diagnostics 已向公眾發佈其 2025 年年度財務報告，並已向金融市場管理局（AMF）提交該報告。該報告可以在他們的網站上訪問。董事會已批准財務報表，並安排於 2026 年 6 月 30 日召開普通和特別股東大會。ABL Diagnostics 專注於分子生物學檢測，擁有多樣化的產品組合，包括針對 HIV、SARS-CoV-2 和其他微生物應用的解決方案。該公司在巴黎泛歐交易所上市，股票代碼為 ABLD
ABL Diagnostics: Availability of the 2025 Annual Financial Report
Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF).
The report can be consulted on the ABL Diagnostics website: https://www.abldiagnostics.com under the section “Newsroom – Legal & Financial News”.
The Board of Directors, which met on April 30, 2025, approved the annual financial statements and decided to convene the shareholders to an Ordinary and Extraordinary General Meeting on June 30, 2026 at 11:00 a.m. at the offices of the law firm De Gaulle Fleurance & Associés, located at 9 rue Boissy d’Anglas, 75008 Paris.
About ABL Diagnostics (ABLD)
ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
- Molecular polymerase chain reaction (PCR) detection – UltraGene, and
- Genotyping by DNA sequencing – DeepChek®.
ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.
ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.
An expanding portfolio of microbiology products:
- HIV – Drug resistance testing, including a whole genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
- Microbiome and taxonomy – 16s/18s RNA-based analyses.
- Other viral and bacterial targets – Comprehensive molecular assays.
Integrated Solutions
- Real-time syndromic PCR tests
- Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
- MediaChek® – Clinical Sample Collection Kits.
ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.
ABL Diagnostics SA
Société anonyme au capital de 1 611 465,60 euros
Headquarters : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ
Tel : +33 (0) 7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260507441661/en/